Furosemide-d5 (Synonyms: Frusemide-d5) |
Catalog No.GC47385
One-Click Copy Product Info
|
An internal standard for the quantification of furosemide
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1189482-35-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Furosemide-d5 is intended for use as an internal standard for the quantification of furosemide by GC- or LC-MS. Furosemide is a loop diuretic and an inhibitor of the Na+/K+/2Cl- (NKCC) cotransporters, NKCC1 and NKCC2 (Kis = ~10 µM for both).1,2 In vivo, furosemide (0.1 mg/kg, p.o.) increases diuresis in beagle dogs.3 Furosemide (30 mg/kg) reduces ventricular collagen deposition and fibrosis in a rat model of dilated cardiomyopathy.4 It is also an inhibitor of carbonic anhydrase I (CAI), CAII, and CAIII (Kis = 0.052-0.065 µM) and organic ion transporter 1 (OAT1; Ki = 9.5 µM), as well as a GABAA receptor antagonist.5,6,7
1.Gillen, C.M., Brill, S., Payne, J.A., et al.Molecular cloning and functional expression of the K-Cl cotransporter from rabbit, rat, and human. A new member of the cation-chloride cotransporter familyJ. Biol. Chem.271(27)16237-16244(1996) 2.Markadieu, N., and Delpire, E.Physiology and pathophysiology of SLC12A1/2 transportersPflugers Arch.466(1)91-105(2014) 3.Potter, B.M., Ames, M.K., Hess, A., et al.Comparison between the effects of torsemide and furosemide on the reninangiotensin-aldosterone system of normal dogsJ. Vet. Cardiol.2651-62(2019) 4.Watanabe, K., Sreedhar, R., Thandavarayan, R.A., et al.Comparative effects of torasemide and furosemide on gap junction proteins and cardiac fibrosis in a rat model of dilated cardiomyopathyBiofactors43(2)187-194(2017) 5.Temperini, C., Cecchi, A., Scozzafava, A., et al.Carbonic anhydrase inhibitors. Interaction of indapamide and related diuretics with 12 mammalian isozymes and X-ray crystallographic studies for the indapamide-isozyme II adductBioorg. Med. Chem. Lett.18(8)2567-2573(2008) 6.Rajan, S.T., Kumar, M.K., and Ramakrishna, M.The novel process for the preparation of (1R,2R,3aS,9aS)-[[2,3,3a,4,9,9a-hexahydro-2-hydroxy-1-[(3S)-3-hydroxyoctyl]-1H-benz[f]inden-5-yl]-oxy]acetic acid(2014) 7.Siess, W., Siegel, F.L., and Lapetina, E.G.Dihomogammalinolenic acid, but not eicosapentaenoic acid, activates washed human plateletsBiochim. Biophys. Acta.801(2)265-276(1984)
| Cas No. | 1189482-35-6 | SDF | |
| Synonymes | Frusemide-d5 | ||
| Canonical SMILES | ClC1=C(S(N)(=O)=O)C=C(C(O)=O)C(NC([2H])([2H])C2=C([2H])C([2H])=C([2H])O2)=C1 | ||
| Formula | C12H6ClD5N2O5S | M.Wt | 335.8 |
| Solubility | DMSO : ≥ 100 mg/mL (297.82 mM) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.978 mL | 14.8898 mL | 29.7796 mL |
| 5 mM | 595.6 μL | 2.978 mL | 5.9559 mL |
| 10 mM | 297.8 μL | 1.489 mL | 2.978 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 28 reference(s) in Google Scholar.)